A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.
🦱 탈모
🔵 RCT
무작위 임상시험
4/5 보강
TL;DR
5% topical minoxidil was superior to placebo on each of the 3 primary efficacy end points: promoting hair growth as measured by change in nonvellus hair count and patient/investigator assessments of hair growth and scalp coverage.
📑 코퍼스 인용 관계
· 인용됨 49
📑 인용한 논문 (6) ▾
- Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation… American journal of clinical dermatology · 2026
- Gender Bias in Topical Minoxidil Labeling and Pricing. The Journal of clinical and aesthetic dermatology · 2025
- Topical minoxidil for androgenetic alopecia: When blood pressure agents make you hairy. Canadian family physician Medecin de famille canadien · 2025
- The pink tax: gender-based cost disparities of topical minoxidil. International journal of women's dermatology · 2025
- Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral … Frontiers in pharmacology · 2025
- Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%… Dermatology practical & conceptual · 2025
연도별 인용 (2012–2026) · 합계 219
OpenAlex 토픽 ·
Hair Growth and Disorders
Dermatology and Skin Diseases
Acne and Rosacea Treatments and Effects
Abstract 🌐 Abstract
[BACKGROUND] To pical minoxidil solution 2% stimulates new hair growth and helps stop the loss of hair in men with androgenetic alopecia and women with female pattern hair loss. Results can be variable, and historic experience suggests that higher concentrations of topical minoxidil may enhance efficacy.
[OBJECTIVE] The purpose of this 48-week, double-blind, placebo-controlled, randomized, multicenter trial was to compare the efficacy and safety of 5% topical minoxidil with 2% topical minoxidil and placebo in the treatment of female pattern hair loss.
[METHODS] A total of 381 women (18-49 years old) with female pattern hair loss applied 5% topical minoxidil solution (n = 153), 2% topical minoxidil solution (n = 154), or placebo (vehicle for 5% solution; n = 74) twice daily. Primary efficacy variables were change in nonvellus hair count at week 48, and patient and investigator assessments of change in hair growth/scalp coverage at week 48.
[RESULTS] After 48 weeks of therapy, 5% topical minoxidil was superior to placebo for each of the 3 primary efficacy measures. The 2% topical minoxidil group demonstrated superiority over placebo for hair count and investigator assessment of hair growth/scalp coverage at week 48; differences in patient assessment of hair growth at week 48 were not significantly different from placebo. The 5% topical minoxidil group demonstrated statistical superiority over the 2% topical minoxidil group in the patient assessment of treatment benefit at week 48. Both 5% and 2% topical minoxidil helped improve psychosocial perceptions of hair loss in women with female pattern hair loss. An increased occurrence of pruritus, local irritation, and hypertrichosis was observed with 5% topical minoxidil versus 2% topical minoxidil and placebo.
[CONCLUSION] In this 48-week study of 381 women with female pattern hair loss, 5% topical minoxidil was superior to placebo on each of the 3 primary efficacy end points: promoting hair growth as measured by change in nonvellus hair count and patient/investigator assessments of hair growth and scalp coverage. Application of 2% topical minoxidil was superior to placebo for assessments of nonvellus hair counts and investigator assessment of hair growth/scalp coverage at week 48; differences in patient assessment of hair growth at week 48 were not significantly different from placebo. At week 48, the 5% topical minoxidil group demonstrated statistical superiority over the 2% topical minoxidil group in the patient assessment of treatment benefit. Both concentrations of topical minoxidil were well tolerated by the women in this trial without evidence of systemic adverse effects. With the introduction of numerous herbal remedies for hair loss, of which most have not been tested in randomized, double-blind, placebo-controlled trials, it is important to describe well-controlled trials that demonstrate the efficacy and safety of topical drugs.
[OBJECTIVE] The purpose of this 48-week, double-blind, placebo-controlled, randomized, multicenter trial was to compare the efficacy and safety of 5% topical minoxidil with 2% topical minoxidil and placebo in the treatment of female pattern hair loss.
[METHODS] A total of 381 women (18-49 years old) with female pattern hair loss applied 5% topical minoxidil solution (n = 153), 2% topical minoxidil solution (n = 154), or placebo (vehicle for 5% solution; n = 74) twice daily. Primary efficacy variables were change in nonvellus hair count at week 48, and patient and investigator assessments of change in hair growth/scalp coverage at week 48.
[RESULTS] After 48 weeks of therapy, 5% topical minoxidil was superior to placebo for each of the 3 primary efficacy measures. The 2% topical minoxidil group demonstrated superiority over placebo for hair count and investigator assessment of hair growth/scalp coverage at week 48; differences in patient assessment of hair growth at week 48 were not significantly different from placebo. The 5% topical minoxidil group demonstrated statistical superiority over the 2% topical minoxidil group in the patient assessment of treatment benefit at week 48. Both 5% and 2% topical minoxidil helped improve psychosocial perceptions of hair loss in women with female pattern hair loss. An increased occurrence of pruritus, local irritation, and hypertrichosis was observed with 5% topical minoxidil versus 2% topical minoxidil and placebo.
[CONCLUSION] In this 48-week study of 381 women with female pattern hair loss, 5% topical minoxidil was superior to placebo on each of the 3 primary efficacy end points: promoting hair growth as measured by change in nonvellus hair count and patient/investigator assessments of hair growth and scalp coverage. Application of 2% topical minoxidil was superior to placebo for assessments of nonvellus hair counts and investigator assessment of hair growth/scalp coverage at week 48; differences in patient assessment of hair growth at week 48 were not significantly different from placebo. At week 48, the 5% topical minoxidil group demonstrated statistical superiority over the 2% topical minoxidil group in the patient assessment of treatment benefit. Both concentrations of topical minoxidil were well tolerated by the women in this trial without evidence of systemic adverse effects. With the introduction of numerous herbal remedies for hair loss, of which most have not been tested in randomized, double-blind, placebo-controlled trials, it is important to describe well-controlled trials that demonstrate the efficacy and safety of topical drugs.
- 표본수 (n) 153
5% topical minoxidil was superior to placebo on each of the 3 primary efficacy end points: promoting hair growth as measured by change in nonvellus hair count and patient/investigator assessments of h
APA 7
Lucky, A. W., Piacquadio, D. J., Ditre, C. M., Dunlap, F., Kantor, I., Pandya, A. G., Savin, R. C., & Tharp, M. D. (2004). A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss.. Journal of the American Academy of Dermatology, 50(4), 541-53. https://doi.org/10.1016/j.jaad.2003.06.014
Vancouver
Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Jour. Amer. Acad. Derm.. 2004;50(4):541-53. doi:10.1016/j.jaad.2003.06.014
AMA 11
Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. Jour. Amer. Acad. Derm.. 2004;50(4):541-53. doi:10.1016/j.jaad.2003.06.014
Chicago
Lucky, A. W., Piacquadio, D. J., Ditre, C. M., Dunlap, F., Kantor, I., Pandya, A. G., Savin, R. C., and Tharp, M. D.. 2004. "A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss." Journal of the American Academy of Dermatology 50 (4): 541-53. https://doi.org/10.1016/j.jaad.2003.06.014
MLA 9
Lucky, A. W., et al. "A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss." Journal of the American Academy of Dermatology, vol. 50, no. 4, 2004, pp. 541-53. doi:10.1016/j.jaad.2003.06.014.
PMID
15034503 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 6/8 (75%)
· 참조 0편 · 후속 6편
이 논문을 인용한 후속 연구 20
- Minoxidil and its use in hair disorders: a review.
- Androgenetic Alopecia: An Update of Treatment Options.
- Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options.
- Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair los…
- Female pattern alopecia: current perspectives.
- Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs.
- The Diagnosis and Treatment of Hair and Scalp Diseases.
- Alopecia Areata: An Updated Review for 2023.
- A randomized, double-blind, vehicle-controlled clinical study of hair regeneration using adipose-der…
- Interventions for female pattern hair loss.
- The Biology and Genomics of Human Hair Follicles: A Focus on Androgenetic Alopecia.
- Hair loss and regeneration performed on animal models.
- Advancing Regenerative Cellular Therapies in Non-Scarring Alopecia.
- Innovative method of alopecia treatment by autologous adipose-derived SVF.
- Female-pattern hair loss: therapeutic update.
- There Is a Positive Dose-Dependent Association between Low-Dose Oral Minoxidil and Its Efficacy for …
- Safety and efficacy of ALRV5XR in women with androgenetic alopecia or telogen effluvium: A randomise…
- Hair regrowth treatment efficacy and resistance in androgenetic alopecia: A systematic review and co…
- Meta-Analysis on the Efficacy and Safety of Traditional Chinese Medicine as Adjuvant Therapy for Ref…
- Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Mi…